Nicola Micale

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6842841/publications.pdf

Version: 2024-02-01

80 papers	2,470 citations	201385 27 h-index	223531 46 g-index
88 all docs	88 docs citations	88 times ranked	2809 citing authors

#	Article	IF	Citations
1	State of the Art on Green Route Synthesis of Gold/Silver Bimetallic Nanoparticles. Molecules, 2022, 27, 1134.	1.7	14
2	Investigation of the influence of chirality and halogen atoms on the anticancer activity of enantiopure palladium(<scp>ii</scp>) complexes derived from chiral amino-alcohol Schiff bases and 2-picolylamine. New Journal of Chemistry, 2022, 46, 6470-6483.	1.4	12
3	Antimicrobial and antiprotozoal activities of silver coordination polymers derived from the asymmetric halogenated Schiff base ligands. Applied Organometallic Chemistry, 2021, 35, e6079.	1.7	11
4	Heteroleptic enantiopure Pd(<scp>ii</scp>)-complexes derived from halogen-substituted Schiff bases and 2-picolylamine: synthesis, experimental and computational characterization and investigation of the influence of chirality and halogen atoms on the anticancer activity. New Journal of Chemistry, 2021, 45, 9163-9180.	1.4	9
5	SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. Biomolecules, 2021, 11, 607.	1.8	97
6	Natural Product-Based Hybrids as Potential Candidates for the Treatment of Cancer: Focus on Curcumin and Resveratrol. Molecules, 2021, 26, 4665.	1.7	17
7	Cytotoxic oxidovanadium(IV) complexes of tridentate halogenâ€substituted Schiff bases: First dinuclear V(IV) complexes with OÂâ†'ÂVIVÂ=ÂOÂâ†'ÂVIVÂ=ÂO core. Bioorganic and Medicinal Chemistry Letters, 2021, 49, 128285.	1.0	3
8	Copper(<scp>ii</scp>) complexes with tridentate halogen-substituted Schiff base ligands: synthesis, crystal structures and investigating the effect of halogenation, leaving groups and ligand flexibility on antiproliferative activities. Dalton Transactions, 2021, 50, 3990-4007.	1.6	28
9	Pseudo-Dipeptide Bearing Î±,Î±-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses. International Journal of Molecular Sciences, 2021, 22, 1398.	1.8	25
10	Hydrogels for the Delivery of Plant-Derived (Poly)Phenols. Molecules, 2020, 25, 3254.	1.7	25
11	Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System. Molecules, 2020, 25, 4454.	1.7	10
12	Peptidyl Fluoromethyl Ketones and Their Applications in Medicinal Chemistry. Molecules, 2020, 25, 4031.	1.7	18
13	Synthesis, Characterization and Anticancer Studies of Rh(I), Rh(III), Pd(II) and Pt(II) Complexes Bearing A Dithiooxamide Ligand. ChemistrySelect, 2020, 5, 810-817.	0.7	3
14	Direct and Chemoselective Synthesis of Tertiary Difluoroketones via Weinreb Amide Homologation with a CHF₂-Carbene Equivalent. Organic Letters, 2019, 21, 8261-8265.	2.4	53
15	Anticancer study of heterobimetallic platinum(II)-ruthenium(II) and platinum(II)-rhodium(III) complexes with bridging dithiooxamide ligand. Journal of Organometallic Chemistry, 2019, 900, 120918.	0.8	15
16	Synthesis, solution behaviour and potential anticancer activity of new trinuclear organometallic palladium(II) complex of {S}-1-phenylethyl dithiooxamide: Comparison with the trinuclear heterobimetallic platinum(II) analogue. Polyhedron, 2019, 164, 195-201.	1.0	9
17	Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker. International Journal of Molecular Sciences, 2019, 20, 945.	1.8	25
18	Ruthenium(<scp>ii</scp>) and palladium(<scp>ii</scp>) homo- and heterobimetallic complexes: synthesis, crystal structures, theoretical calculations and biological studies. Dalton Transactions, 2019, 48, 15869-15887.	1.6	8

#	Article	IF	Citations
19	Synthesis and Anti-HIV Profile of a Novel Tetrahydroindazolylbenzamide Derivative Obtained by Oxazolone Chemistry. ACS Medicinal Chemistry Letters, 2019, 10, 398-401.	1.3	8
20	Discovery of benzimidazoleâ€based Leishmania mexicana cysteine protease <scp>CPB</scp>2.8Î”<scp>CTE</scp> inhibitors as potential therapeutics for leishmaniasis. Chemical Biology and Drug Design, 2018, 92, 1585-1596.	1.5	22
21	Ensembleâ€based ADMEâ€“Tox profiling and virtual screening for the discovery of new inhibitors of the Leishmania mexicana cysteine protease CPB2.8Î”CTE. Chemical Biology and Drug Design, 2018, 91, 597-604.	1.5	10
22	â€œClickâ€•on PLGAâ€PEG and hyaluronic acid: Gaining access to antiâ€leishmanial pentamidine bioconjugates. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2018, 106, 2778-2785.	1.6	24
23	Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents. BioMetals, 2017, 30, 313-320.	1.8	24
24	Silibinin-conjugated graphene nanoplatform: Synthesis, characterization and biological evaluation. FlatChem, 2017, 1, 34-41.	2.8	17
25	Synthesis of C3/C1-Substituted Tetrahydroisoquinolines. Molecules, 2015, 20, 14902-14914.	1.7	17
26	Peptideâ€Based Proteasome Inhibitors in Anticancer Drug Design. Medicinal Research Reviews, 2014, 34, 1001-1069.	5.0	46
27	Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. European Journal of Medicinal Chemistry, 2014, 83, 1-14.	2.6	27
28	Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities. Journal of Inorganic Biochemistry, 2014, 141, 79-82.	1.5	27
29	Development of Novel Selective Peptidomimetics Containing a Boronic Acid Moiety, Targeting the 20S Proteasome as Anticancer Agents. ChemMedChem, 2014, 9, 1801-1816.	1.6	16
30	Identification of a new series of amides as non-covalent proteasome inhibitors. European Journal of Medicinal Chemistry, 2014, 76, 1-9.	2.6	25
31	Inhibition of Rhodesain as a Novel Therapeutic Modality for Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2013, 56, 5637-5658.	2.9	77
32	Synthesis and biological evaluation of new 2-amino-6-(trifluoromethoxy)benzoxazole derivatives, analogues of riluzole. Medicinal Chemistry Research, 2013, 22, 6089-6095.	1.1	4
33	Development of peptidomimetic boronates as proteasome inhibitors. European Journal of Medicinal Chemistry, 2013, 64, 23-34.	2.6	34
34	Peptide-based boronates: How to achieve tissue specificity in anticancer therapy. World Journal of Translational Medicine, 2013, 2, 32.	3.5	0
35	Mechanism of falcipain-2 inhibition by Î±,Î²-unsaturated benzo[1,4]diazepin-2-one methyl ester. Journal of Computer-Aided Molecular Design, 2012, 26, 1035-1043.	1.3	24
36	Synthesis of benzothiazole derivatives and their biological evaluation as anticancer agents. Medicinal Chemistry Research, 2012, 21, 2644-2651.	1.1	27

#	Article	IF	Citations
37	Mechanism of Inhibition of GluA2 AMPA Receptor Channel Opening by 2,3-Benzodiazepine Derivatives: Functional Consequences of Replacing a 7,8-Methylenedioxy with a 7,8-Ethylenedioxy Moiety. Biochemistry, 2012, 51, 1787-1795.	1.2	17
38	Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipainâ€2 Inhibitors. ChemMedChem, 2012, 7, 1594-1600.	1.6	27
39	Mechanism of Inhibition of the GluA2 AMPA Receptor Channel Opening: The Role of 4-Methyl versus 4-Carbonyl Group on the Diazepine Ring of 2,3-Benzodiazepine Derivatives. ACS Chemical Neuroscience, 2011, 2, 506-513.	1.7	23
40	Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro. Journal of Inorganic Biochemistry, 2011, 105, 1576-1579.	1.5	19
41	Development of Novel Peptidomimetics Containing a Vinyl Sulfone Moiety as Proteasome Inhibitors. ChemMedChem, 2011, 6, 1228-1237.	1.6	47
42	Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 2058-2065.	2.6	30
43	Falcipainâ€2 inhibitors. Medicinal Research Reviews, 2010, 30, 136-167.	5.0	121
44	Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 4928-4938.	1.4	31
45	Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain. European Journal of Medicinal Chemistry, 2010, 45, 3228-3233.	2.6	34
46	Synthesis, Chiral Resolution and Pharmacological Evaluation of a 2,3-Benzodiazepine-Derived Noncompetitive AMPA Receptor Antagonist. ChemMedChem, 2009, 4, 415-420.	1.6	1
47	Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 6505-6511.	1.4	28
48	Novel Peptidomimetics Containing a Vinyl Ester Moiety as Highly Potent and Selective Falcipain-2 Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 2157-2160.	2.9	73
49	Nonpeptidic Vinyl and Allyl Phosphonates as Falcipainâ€2 Inhibitors. ChemMedChem, 2008, 3, 1030-1033.	1.6	44
50	Structureâ€“activity study of 2,3-benzodiazepin-4-ones noncompetitive AMPAR antagonists: Identification of the 1-(4-amino-3-methylphenyl)-3,5-dihydro-7,8-ethylenedioxy-4H-2,3-benzodiazepin-4-one as neuroprotective agent. Bioorganic and Medicinal Chemistry, 2008, 16, 2200-2211.	1.4	23
51	Mechanism of Inhibition of the GluR2 AMPA Receptor Channel Opening by 2,3-Benzodiazepine Derivatives. Biochemistry, 2008, 47, 1061-1069.	1.2	22
52	Development of Peptidomimetics with a Vinyl Sulfone Warhead as Irreversible Falcipain-2 Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 988-996.	2.9	196
53	N-Hydroxypyrazolyl Glycine Derivatives as Selective N-Methyl-d-aspartic Acid Receptor Ligands. Journal of Medicinal Chemistry, 2008, 51, 4179-4187.	2.9	19
54	Enantioseparation, absolute configuration determination, and anticonvulsant activity of (Â±)-1-(4-aminophenyl)-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-one. Chirality, 2007, 19, 16-21.	1.3	3

#	Article	IF	Citations
55	Chloro-substituted Hoveydaâ€“Grubbs ruthenium carbene: Investigation of electronic effects. Journal of Organometallic Chemistry, 2007, 692, 3574-3576.	0.8	26
56	Subunit-Specific Agonist Activity at NR2A-, NR2B-, NR2C-, and NR2D-ContainingN-Methyl-d-aspartate Glutamate Receptors. Molecular Pharmacology, 2007, 72, 907-920.	1.0	151
57	Novel Peptidomimetic Cysteine Protease Inhibitors as Potential Antimalarial Agents. Journal of Medicinal Chemistry, 2006, 49, 3064-3067.	2.9	71
58	Synthesis, Chiral Resolution, and Enantiopharmacology of a Potent 2,3-Benzodiazepine Derivative as Noncompetitive AMPA Receptor Antagonist. Journal of Medicinal Chemistry, 2006, 49, 575-581.	2.9	35
59	New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 167-170.	1.0	23
60	Enantioselective recognition of 2,3-benzodiazepin-4-one derivatives with anticonvulsant activity on several polysaccharide chiral stationary phases. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 838, 56-62.	1.2	14
61	Synthesis of Novel 3-(Alkylcarbamoyl)-2-aryl-1,2-dihydro-6,7-(methylenedioxy)-3H-quinazolin-4-ones as Anticonvulsant Agents. Chemistry and Biodiversity, 2006, 3, 304-311.	1.0	4
62	Synthesis of 2-semicarbazonomethyl-4,5-methylenedioxyphenylacetic acids as anticonvulsant agents. Il Farmaco, 2005, 60, 231-235.	0.9	6
63	1-Aryl-6,7-methylenedioxy-3H-quinazolin-4-ones as Anticonvulsant Agents.. ChemInform, 2004, 35, no.	0.1	0
64	Design of 1-substituted 2-arylmethyl-4,5-methylenedioxybenzene derivatives as antiseizure agents. Bioorganic and Medicinal Chemistry, 2004, 12, 3703-3709.	1.4	10
65	Design and Synthesis of a Potent and Selective Peptidomimetic Inhibitor of Caspase-3. Journal of Medicinal Chemistry, 2004, 47, 6455-6458.	2.9	38
66	1-Aryl-6,7-methylenedioxy-3 H -quinazolin-4-ones as anticonvulsant agents. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4427-4430.	1.0	59
67	Synthesis and cytotoxic activity of 1,3-benzodioxole derivatives. Note II. Il Farmaco, 2003, 58, 351-355.	0.9	19
68	Synthesis and Antitumor Activity of 1,3-Benzodioxole Derivatives.. ChemInform, 2003, 34, no.	0.1	0
69	Synthesis and Cytotoxic Activity of 1,3-Benzodioxole Derivatives. Part 2.. ChemInform, 2003, 34, no.	0.1	1
70	5-Phenyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-8(7H)-one. Acta Crystallographica Section C: Crystal Structure Communications, 2003, 59, o117-o119.	0.4	2
71	Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 443-446.	1.0	17
72	A SIMPLE AND EFFICIENT SYNTHESIS OF GYKI 52466 AND GYKI 52895. Synthetic Communications, 2002, 32, 527-533.	1.1	12

#	Article	IF	Citations
73	Synthesis and antitumor activity of 1,3-benzodioxole derivatives. Il Farmaco, 2002, 57, 853-859.	0.9	31
74	Novel Potent AMPA/Kainate Receptor Antagonists:Â Synthesis and Anticonvulsant Activity of a Series of 2-[(4-Alkylsemicarbazono)-(4-amino- phenyl)methyl]-4,5-methylenedioxyphenylacetic Acid Alkyl Esters. Journal of Medicinal Chemistry, 2002, 45, 4433-4442.	2.9	14
75	Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8-methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-ones. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 463-466.	1.0	24
76	Synthesis and in vitro antitumour activity evaluation of 1-aryl-1H,3H-thiazolo[4,3-b]quinazolines. European Journal of Medicinal Chemistry, 2000, 35, 1115-1119.	2.6	37
77	Synthesis and Anticonvulsant Activity of Novel and Potent 6,7-Methylenedioxyphthalazin-1(2H)-ones. Journal of Medicinal Chemistry, 2000, 43, 2851-2859.	2.9	193
78	Synthesis and Anticonvulsant Activity of Novel and Potent 2,3-Benzodiazepine AMPA/Kainate Receptor Antagonists. Journal of Medicinal Chemistry, 1999, 42, 4414-4421.	2.9	48
79	Synthesis and anticonvulsant activity of new 2,3-benzodiazepines as AMPA receptor antagonists. Il Farmaco, 1999, 54, 178-187.	0.9	27
80	7,8-Methylenedioxy-4H-2,3-benzodiazepin-4-ones as novel AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 971-976.	1.0	39